https://lifordi.reportablenews.com daily 1.0 https://lifordi.reportablenews.com/pr/lifordi-immunotherapeutics-presents-phase-1-clinical-data-for-lfd-200-a-subcutaneous-glucocorticoid-antibody-drug-conjugate-at-eular-2026 2026-06-08T11:30:40Z monthly 0.5 https://lifordi.reportablenews.com/pr/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors 2025-11-18T17:01:11Z monthly 0.5 https://lifordi.reportablenews.com/pr/lifordi-presents-nonclinical-data-on-glucocorticoid-adc-and-initiates-ph-1-in-ra 2025-10-27T11:31:41Z monthly 0.5 https://lifordi.reportablenews.com/pr/lifordi-immunotherapeutics-to-present-new-preclinical-data-on-antibody-drug-conjugate-lfd-200-demonstrating-selective-and-sustained-delivery-of-glucocorticoid-payload-to-immune-tissues-without-evidence-of-toxicity 2025-10-10T13:07:53Z monthly 0.5 https://lifordi.reportablenews.com/pr/lifordi-immunotherapeutics-presents-preclinical-data-on-glucocorticoid-antibody-drug-conjugate-lfd-200-to-treat-autoimmune-and-inflammatory-diseases-at-eular-2025 2025-06-11T12:33:41Z monthly 0.5 https://lifordi.reportablenews.com/pr/lifordi-immunotherapeutics-appoints-matthew-w-mcclure-m-d-as-chief-medical-officer 2025-01-09T13:15:00Z monthly 0.5 https://lifordi.reportablenews.com/pr/lifordi-reveals-70-mm-series-a_named-endpoints-11-winner 2024-09-27T12:04:53Z monthly 0.5